vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Tivic Health Systems, Inc. (TIVC). Click either name above to swap in a different company.
Aligos Therapeutics, Inc. is the larger business by last-quarter revenue ($169.0K vs $146.0K, roughly 1.2× Tivic Health Systems, Inc.). On growth, Tivic Health Systems, Inc. posted the faster year-over-year revenue change (15.9% vs -72.1%). Over the past eight quarters, Tivic Health Systems, Inc.'s revenue compounded faster (-36.0% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Tivic Health Systems, Inc. is a medical technology firm that develops and sells non-invasive, drug-free bioelectronic devices for chronic health condition management. Its flagship product relieves sinus pain and congestion, serving US consumer healthcare markets, with ongoing R&D for new devices targeting other common ailments.
ALGS vs TIVC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $146.0K |
| Net Profit | — | $-2.6M |
| Gross Margin | — | -99.3% |
| Operating Margin | — | -1700.7% |
| Net Margin | — | -1778.1% |
| Revenue YoY | -72.1% | 15.9% |
| Net Profit YoY | 75.8% | -81.4% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | — | ||
| Q3 25 | $741.0K | $146.0K | ||
| Q2 25 | $965.0K | $86.0K | ||
| Q1 25 | $311.0K | $70.0K | ||
| Q4 24 | $606.0K | $180.0K | ||
| Q3 24 | $1.3M | $126.0K | ||
| Q2 24 | $1.1M | $140.0K | ||
| Q1 24 | $694.0K | $334.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-31.5M | $-2.6M | ||
| Q2 25 | $-15.9M | $-1.9M | ||
| Q1 25 | $43.1M | $-1.5M | ||
| Q4 24 | $-82.2M | $-1.5M | ||
| Q3 24 | $-19.3M | $-1.4M | ||
| Q2 24 | $5.1M | $-1.3M | ||
| Q1 24 | $-34.9M | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | -99.3% | ||
| Q2 25 | — | 62.8% | ||
| Q1 25 | — | 71.4% | ||
| Q4 24 | — | -132.8% | ||
| Q3 24 | — | 34.9% | ||
| Q2 24 | — | 21.4% | ||
| Q1 24 | — | 50.0% |
| Q4 25 | — | — | ||
| Q3 25 | -3827.4% | -1700.7% | ||
| Q2 25 | -1924.0% | -2248.8% | ||
| Q1 25 | -6187.5% | -2151.4% | ||
| Q4 24 | -3393.2% | -165.6% | ||
| Q3 24 | -1610.5% | -1135.7% | ||
| Q2 24 | -2489.5% | -904.3% | ||
| Q1 24 | -3176.7% | -443.4% |
| Q4 25 | — | — | ||
| Q3 25 | -4256.0% | -1778.1% | ||
| Q2 25 | -1643.8% | -2245.3% | ||
| Q1 25 | 13854.7% | -2145.7% | ||
| Q4 24 | -13556.1% | -820.6% | ||
| Q3 24 | -1540.7% | -1135.7% | ||
| Q2 24 | 477.0% | -904.3% | ||
| Q1 24 | -5023.5% | -443.4% |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | — | ||
| Q2 25 | $-1.53 | $-2.19 | ||
| Q1 25 | $-2.11 | $-2.52 | ||
| Q4 24 | $-13.10 | $3.07 | ||
| Q3 24 | $-3.07 | $-0.23 | ||
| Q2 24 | $0.81 | $-5.37 | ||
| Q1 24 | $-5.58 | $-17.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $3.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $3.4M |
| Total Assets | $88.5M | $6.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | $3.5M | ||
| Q2 25 | $122.9M | $1.2M | ||
| Q1 25 | $137.9M | $669.0K | ||
| Q4 24 | $56.9M | $2.0M | ||
| Q3 24 | $74.9M | $2.2M | ||
| Q2 24 | $94.5M | $3.7M | ||
| Q1 24 | $112.7M | $1.7M |
| Q4 25 | $53.5M | — | ||
| Q3 25 | $71.8M | $3.4M | ||
| Q2 25 | $101.9M | $3.3M | ||
| Q1 25 | $116.4M | $3.0M | ||
| Q4 24 | $-29.0M | $2.5M | ||
| Q3 24 | $50.1M | $2.8M | ||
| Q2 24 | $67.2M | $4.2M | ||
| Q1 24 | $59.8M | $2.2M |
| Q4 25 | $88.5M | — | ||
| Q3 25 | $109.8M | $6.2M | ||
| Q2 25 | $134.7M | $4.5M | ||
| Q1 25 | $150.7M | $3.8M | ||
| Q4 24 | $70.1M | $2.8M | ||
| Q3 24 | $88.4M | $3.4M | ||
| Q2 24 | $108.8M | $4.8M | ||
| Q1 24 | $127.9M | $3.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -1374.0% |
| Capex IntensityCapex / Revenue | — | 6.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | — | ||
| Q3 25 | $-24.3M | $-2.0M | ||
| Q2 25 | $-15.5M | $-1.8M | ||
| Q1 25 | $-20.9M | $-889.0K | ||
| Q4 24 | $-18.4M | $-1.4M | ||
| Q3 24 | $-20.1M | $-1.4M | ||
| Q2 24 | $-19.5M | $-1.3M | ||
| Q1 24 | $-22.7M | $-1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-2.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1374.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 6.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
